Pain Therapeutics (PTIE) Shares Down 7.7%

Pain Therapeutics, Inc. (NASDAQ:PTIE) was down 7.7% during trading on Thursday . The company traded as low as $8.35 and last traded at $8.51. Approximately 897,272 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 4,567,459 shares. The stock had previously closed at $9.22.

A number of equities research analysts have recently commented on PTIE shares. Zacks Investment Research cut shares of Pain Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 19th. ValuEngine cut shares of Pain Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st.

The firm has a market cap of $56.13, a PE ratio of -4.15 and a beta of 2.11.

Pain Therapeutics (NASDAQ:PTIE) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter. equities analysts forecast that Pain Therapeutics, Inc. will post -1.9 EPS for the current year.

A hedge fund recently bought a new stake in Pain Therapeutics stock. Dimensional Fund Advisors LP acquired a new position in shares of Pain Therapeutics, Inc. (NASDAQ:PTIE) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 59,989 shares of the biopharmaceutical company’s stock, valued at approximately $247,000. Dimensional Fund Advisors LP owned about 0.91% of Pain Therapeutics at the end of the most recent quarter. 35.99% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This report was first posted by Stock Observer and is the property of of Stock Observer. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at

About Pain Therapeutics

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply